Risks and benefits of gene therapy and transplantation in sickle cell disease. Comment on: "HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial"

Mariane de Montalembert; Haydar Frangoul

doi:10.3324/haematol.2026.301370

Comments

Risks and benefits of gene therapy and transplantation in sickle cell disease. Comment on: "HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial"

Mariane de Montalembert
Haydar Frangoul

Department of General Pediatrics and Pediatric Infectious Diseases, Sickle Cell Center, Necker-Enfants Malades Hospital, Assistance Publique – Hopitaux de Paris (AP-HP); InIdex GREx, Universite Paris Cite; INSERM, EFS, BIGR U1134, 75015, Paris

Sarah Cannon Research Institute at The Children’s Hospital at TriStar Centennial, Nashville, TN

Haematologica Early view Jul 23, 2026 https://doi.org/10.3324/haematol.2026.301370

Abstract

Not available.

Figures & Tables

Article Information

Early view : Comments

DOI

https://doi.org/10.3324/haematol.2026.301370

Published

2026-07-23

Published By

Ferrata Storti Foundation, Pavia, Italy

Print ISSN

0390-6078

Online ISSN

1592-8721

Copyright & Usage

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Article Usage

Online Views

119

PDF Downloads

81

No Data

PlumX

Risks and benefits of gene therapy and transplantation in sickle cell disease. Comment on: "HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial"

Abstract

Figures & Tables

Article Information

Article Usage

Download Citation

Navigate

For Authors

For Reviewers

For Advertisers

Education

Privacy

More